These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 37223682)

  • 1. Optimal
    Zuo Y; Liu Q; Li N; Li P; Zhang J; Song S
    Front Oncol; 2023; 13():1173355. PubMed ID: 37223682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of multi-center
    Zuo Y; Liu L; Chang C; Yan H; Wang L; Sun D; Ruan M; Lei B; Xia X; Xie W; Song S; Huang G
    Med Phys; 2024 Jul; 51(7):4872-4887. PubMed ID: 38285641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting EGFR mutation subtypes in lung adenocarcinoma using
    Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S
    Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of radiomics based on
    Zhou Y; Ma XL; Zhang T; Wang J; Zhang T; Tian R
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2904-2913. PubMed ID: 33547553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of
    Li S; Li Y; Zhao M; Wang P; Xin J
    Korean J Radiol; 2022 Sep; 23(9):921-930. PubMed ID: 36047542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs.
    Yang L; Xu P; Li M; Wang M; Peng M; Zhang Y; Wu T; Chu W; Wang K; Meng H; Zhang L
    Front Oncol; 2022; 12():894323. PubMed ID: 35800046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of
    Zhang M; Bao Y; Rui W; Shangguan C; Liu J; Xu J; Lin X; Zhang M; Huang X; Zhou Y; Qu Q; Meng H; Qian D; Li B
    Front Oncol; 2020; 10():568857. PubMed ID: 33134170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma.
    Chang C; Zhou S; Yu H; Zhao W; Ge Y; Duan S; Wang R; Qian X; Lei B; Wang L; Liu L; Ruan M; Yan H; Sun X; Xie W
    Eur Radiol; 2021 Aug; 31(8):6259-6268. PubMed ID: 33544167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiomics analysis for the differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma in
    Zhang Y; Cheng C; Liu Z; Wang L; Pan G; Sun G; Chang Y; Zuo C; Yang X
    Med Phys; 2019 Oct; 46(10):4520-4530. PubMed ID: 31348535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of [
    Gao J; Niu R; Shi Y; Shao X; Jiang Z; Ge X; Wang Y; Shao X
    EJNMMI Res; 2023 Apr; 13(1):26. PubMed ID: 37014500
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Yang B; Ji HS; Zhou CS; Dong H; Ma L; Ge YQ; Zhu CH; Tian JH; Zhang LJ; Zhu H; Lu GM
    Transl Lung Cancer Res; 2020 Jun; 9(3):563-574. PubMed ID: 32676320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of EGFR mutation status in lung adenocarcinoma based on
    Tan JL; Xia L; Sun SG; Zeng H; Lu DY; Cheng XJ
    Am J Nucl Med Mol Imaging; 2023; 13(5):230-244. PubMed ID: 38023818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subregion-specific
    Wang Y; Yang G; Gao X; Li L; Zhu H; Yi H
    Am J Nucl Med Mol Imaging; 2024; 14(2):134-143. PubMed ID: 38737644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on
    Koyasu S; Nishio M; Isoda H; Nakamoto Y; Togashi K
    Ann Nucl Med; 2020 Jan; 34(1):49-57. PubMed ID: 31659591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Contrasted CT Radiomics for SAH Prognosis Prediction.
    Shan D; Wang J; Qi P; Lu J; Wang D
    Bioengineering (Basel); 2023 Aug; 10(8):. PubMed ID: 37627852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of pre-therapy
    Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation.
    Cheng B; Deng H; Zhao Y; Xiong J; Liang P; Li C; Liang H; Shi J; Li J; Xiong S; Lai T; Chen Z; Wu J; Qian T; Huan W; Ng MTA; He J; Liang W
    Eur Radiol; 2022 Sep; 32(9):5869-5879. PubMed ID: 35348863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric MRI-Based Radiomics Approaches for Preoperative Prediction of EGFR Mutation Status in Spinal Bone Metastases in Patients with Lung Adenocarcinoma.
    Jiang X; Ren M; Shuang X; Yang H; Shi D; Lai Q; Dong Y
    J Magn Reson Imaging; 2021 Aug; 54(2):497-507. PubMed ID: 33638577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
    Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
    Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging phenotyping using
    Zhou L; Sun J; Long H; Zhou W; Xia R; Luo Y; Fang J; Wang Y; Chen X
    Insights Imaging; 2024 Jan; 15(1):5. PubMed ID: 38185779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.